Results 11 to 20 of about 140,776 (178)

Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study [PDF]

Annals of Clinical and Translational Neurology, 2021
Objective Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower rate of disease progression.
Steve Vucic, Robert D. Henderson, Susan Mathers, Merrilee Needham, David Schultz, Matthew C. Kiernan, the TEALS study group   +6 more
doaj   +4 more sources

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes [PDF]

Redox Biology, 2015
Oxidative stress contributes to pathology associated with inflammatory brain disorders and therapies that upregulate antioxidant pathways may be neuroprotective in diseases such as multiple sclerosis.
He Huang, Alexandra Taraboletti, Leah P. Shriver   +2 more
doaj   +2 more sources

Effects of dimethyl fumarate on neuroprotection and immunomodulation

Journal of Neuroinflammation, 2012
Background Neuronal degeneration in multiple sclerosis has been linked to oxidative stress. Dimethyl fumarate is a promising novel oral therapeutic option shown to reduce disease activity and progression in patients with relapsing-remitting multiple ...
Albrecht Philipp, Bouchachia Imane, Goebels Norbert, Henke Nadine, Hofstetter Harald H, Issberner Andrea, Kovacs Zsuzsa, Lewerenz Jan, Lisak Dmitrij, Maher Pamela, Mausberg Anne-Kathrin, Quasthoff Kim, Zimmermann Corinna, Hartung Hans-Peter, Methner Axel   +14 more
doaj   +2 more sources

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia.
Guy Buckle, Daniel Bandari, Jeffrey Greenstein, Mark Gudesblatt, Bhupendra Khatri, Mariko Kita, Pavle Repovic, Emily Riser, Bianca Weinstock-Guttman, Ben Thrower, Sherrill Loring, Katherine Riester, Nick Everage, Claudia Prada, Irene Koulinska, Monica Mann   +15 more
doaj   +3 more sources

Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. [PDF]

PLoS ONE, 2015
Dimethyl fumarate is an immunomodulatory and neuroprotective drug, approved recently for the treatment of relapsing-remitting multiple sclerosis. In view of the limited therapeutic options for human acute and chronic polyneuritis, we used the animal ...
Kalliopi Pitarokoili, Björn Ambrosius, Daniela Meyer, Lisa Schrewe, Ralf Gold   +4 more
doaj   +4 more sources

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS

Неврология, нейропсихиатрия, психосоматика, 2016
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral
V. R. Mkrtchyan, L. V. Brylev, I. A. Shpak, A. M. Sergeev   +3 more
doaj   +2 more sources

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017
Background Dimethyl fumarate and fingolimod are oral disease-modifying therapies approved to treat relapsing multiple sclerosis. Prior observational studies and our previous 12-month investigation showed comparable clinical efficacy.
Carrie M Hersh, Thomas E Love, Anasua Bandyopadhyay, Samuel Cohn, Claire Hara-Cleaver, Robert A Bermel, Robert J Fox, Jeffrey A Cohen, Daniel Ontaneda   +8 more
doaj   +2 more sources

Persisting lymphopenia and dimethyl fumarate: A clinical commentary. [PDF]

, 2021
Severe prolonged lymphopenia as rare side-effect of dimethyl fumarate is mostly reversible. Caldito et al. report a case of persistent severe lymphopenia over 5 years after discontinuation of dimethyl fumarate.
Chan, Andrew, Diem, Lara
core   +2 more sources

New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo

Communications Biology, 2023
Dimethyl fumarate is an ester from the Krebs cycle intermediate fumarate. This drug is approved and currently used for the treatment of psoriasis and multiple sclerosis, and its anti-angiogenic activity was reported some years ago.
Mª Carmen Ocaña, Manuel Bernal, Chendong Yang, Carlos Caro, Alejandro Domínguez, Hieu S. Vu, Casimiro Cárdenas, María Luisa García-Martín, Ralph J. DeBerardinis, Ana R. Quesada, Beatriz Martínez-Poveda, Miguel Ángel Medina   +11 more
doaj   +1 more source

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

, 2023
IMPORTANCE: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses.
Butler, Ernest, Eichau, Sara, Kuhle, Jens, Yamout, Bassem, Khoury, Samia J., Khoury, Samia J, Butzkueven, Helmut, Macdonell, Richard A. L., Prat, Alexandre, MSBase Study Grp, MSBase Study Grp, Laureys, Guy, Grand'Maison, Francois, MSBase Study Group, [missing], Alroughani, Raed, Terzi, Murat, Slee, Mark, Barnett, Michael, Van Hijfte, Liesbeth, Sa, Maria Jose, Zhu, Chao, Gerlach, Oliver, Horakova, Dana, Macdonell, Richard A L, Skibina, Olga, Ozakbas, Serkan, Izquierdo, Guillermo, Garber, Justin, Van Pesch, Vincent, Van Wijmeersch, Bart, Lechner-Scott, Jeannette, Boz, Cavit, Patti, Francesco, Weinstock-Guttman, Bianca, Girard, Marc, Kermode, Allan G, Duquette, Pierre, Zhou, Zhen, Hodgkinson, Suzanne, Buzzard, Katherine, Prevost, Julie, Jokubaitis, Vilija, MSBase Study Group, Grammond, Pierre, Monif, Mastura, Kalincik, Tomas, Grand’Maison, Francois, Kermode, Allan G., Merlo, Daniel, van der Walt, Anneke   +48 more
core   +2 more sources